Loading…
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy
We aimed to assess the prognostic role of neutrophilia, lymphocytopenia and the neutrophil-to-lymphocyte ratio (NLR), and to design models to define the prognosis of patients receiving first-line chemo- or targeted therapy for advanced non-small cell lung cancer (NSCLC). We retrospectively analysed...
Saved in:
Published in: | Oncotarget 2016-05, Vol.7 (18), p.26916-26924 |
---|---|
Main Authors: | , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c354t-1ad8abab6426eed4b47fd4924b852ea058a8b06cc906a26c1514137729b2f8423 |
---|---|
cites | cdi_FETCH-LOGICAL-c354t-1ad8abab6426eed4b47fd4924b852ea058a8b06cc906a26c1514137729b2f8423 |
container_end_page | 26924 |
container_issue | 18 |
container_start_page | 26916 |
container_title | Oncotarget |
container_volume | 7 |
creator | Berardi, Rossana Rinaldi, Silvia Santoni, Matteo Newsom-Davis, Thomas Tiberi, Michela Morgese, Francesca Caramanti, Miriam Savini, Agnese Ferrini, Consuelo Torniai, Mariangela Fiordoliva, Ilaria Bower, Marc Cascinu, Stefano |
description | We aimed to assess the prognostic role of neutrophilia, lymphocytopenia and the neutrophil-to-lymphocyte ratio (NLR), and to design models to define the prognosis of patients receiving first-line chemo- or targeted therapy for advanced non-small cell lung cancer (NSCLC).
We retrospectively analysed 401 consecutive patients with advanced NSCLC treated with first line chemo- or targeted therapy. Patients were stratified into two groups with pre-treatment NLR ≥ 3.7 (Group A) vs. < 3.7 (Group B). The best NLR cut-off was identified by ROC curve analysis.
At baseline 264 patients had NLR≥3.7 (Group A), whilst 137 had lower NLR (Group B). Median OS was 10.8 months and 19.4 months in the two groups (p < 0.001), while median PFS was 3.6 months and 5.6 months, respectively (p = 0.012). At multivariate analysis, ECOG-PS≥2, stage IV cancer, non-adenocarcinoma histology, EGFR wild-type status and NLR were predictors of worse OS. Stage IV cancer, wild type EGFR status and NLR≥3.7 were independent prognostic factors for worse PFS. Patients were stratified according to the presence of 0-1 prognostic factors (8%), 2-3 factors (73%) and 4-5 factors (19%) and median OS in these groups was 33.7 months, 14.6 months and 6.6 months, respectively (p < 0.001). Similarly, patients were stratified for PFS based on the presence of 0-1 prognostic factor (15%), 2 factors (41%) and 3 factors (44%). The median PFS was 8.3 months, 4.6 months and 3.3 months respectively (p < 0.001).
Pre-treatment NLR is an independent prognostic factor for patients with advanced NSCLC treated with first-line therapies. |
doi_str_mv | 10.18632/oncotarget.8309 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5042025</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1812888884</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-1ad8abab6426eed4b47fd4924b852ea058a8b06cc906a26c1514137729b2f8423</originalsourceid><addsrcrecordid>eNpVkUtv3SAQhVHVqImS7LuKWHbjBDDYeBOpivqSIrWLdo3GeHwvkQ0O4FvlR_Q_l3vzaDoLQJrvHAYOIe85u-S6qcVV8DZkiBvMl7pm3RtywjvZVUKp-u2r8zE5T-mOlVKy1aJ7R45Fy0THanVC_vyIYeNDys7SOQw4JZoDXSIOzmaa1rhzO5io83SB7NDnRH-7vKUw7MBbHKgPvkozTBO1WJZp9Rtq961Ic0TIBTkIRhdTribnkdotzqGioRCH6QuStxhheTgjRyNMCc-f9lPy6_Onnzdfq9vvX77dfLytbK1krjgMGnroGykaxEH2sh0H2QnZayUQmNKge9ZY27EGRGO54pLXbSu6XoxaivqUXD_6Lms_42DLuyJMZoluhvhgAjjzf8e7rdmEnVFMCiZUMfjwZBDD_Yopm9ml_QeAx7AmwzUXel-yoOwRtTGkFHF8uYYzcwjS_AvS7IMskovX470InmOr_wLP26Bl</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1812888884</pqid></control><display><type>article</type><title>Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy</title><source>PubMed Central</source><creator>Berardi, Rossana ; Rinaldi, Silvia ; Santoni, Matteo ; Newsom-Davis, Thomas ; Tiberi, Michela ; Morgese, Francesca ; Caramanti, Miriam ; Savini, Agnese ; Ferrini, Consuelo ; Torniai, Mariangela ; Fiordoliva, Ilaria ; Bower, Marc ; Cascinu, Stefano</creator><creatorcontrib>Berardi, Rossana ; Rinaldi, Silvia ; Santoni, Matteo ; Newsom-Davis, Thomas ; Tiberi, Michela ; Morgese, Francesca ; Caramanti, Miriam ; Savini, Agnese ; Ferrini, Consuelo ; Torniai, Mariangela ; Fiordoliva, Ilaria ; Bower, Marc ; Cascinu, Stefano</creatorcontrib><description>We aimed to assess the prognostic role of neutrophilia, lymphocytopenia and the neutrophil-to-lymphocyte ratio (NLR), and to design models to define the prognosis of patients receiving first-line chemo- or targeted therapy for advanced non-small cell lung cancer (NSCLC).
We retrospectively analysed 401 consecutive patients with advanced NSCLC treated with first line chemo- or targeted therapy. Patients were stratified into two groups with pre-treatment NLR ≥ 3.7 (Group A) vs. < 3.7 (Group B). The best NLR cut-off was identified by ROC curve analysis.
At baseline 264 patients had NLR≥3.7 (Group A), whilst 137 had lower NLR (Group B). Median OS was 10.8 months and 19.4 months in the two groups (p < 0.001), while median PFS was 3.6 months and 5.6 months, respectively (p = 0.012). At multivariate analysis, ECOG-PS≥2, stage IV cancer, non-adenocarcinoma histology, EGFR wild-type status and NLR were predictors of worse OS. Stage IV cancer, wild type EGFR status and NLR≥3.7 were independent prognostic factors for worse PFS. Patients were stratified according to the presence of 0-1 prognostic factors (8%), 2-3 factors (73%) and 4-5 factors (19%) and median OS in these groups was 33.7 months, 14.6 months and 6.6 months, respectively (p < 0.001). Similarly, patients were stratified for PFS based on the presence of 0-1 prognostic factor (15%), 2 factors (41%) and 3 factors (44%). The median PFS was 8.3 months, 4.6 months and 3.3 months respectively (p < 0.001).
Pre-treatment NLR is an independent prognostic factor for patients with advanced NSCLC treated with first-line therapies.</description><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.8309</identifier><identifier>PMID: 27029035</identifier><language>eng</language><publisher>United States: Impact Journals LLC</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - therapeutic use ; Area Under Curve ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - pathology ; Clinical Research Papers ; Disease-Free Survival ; ErbB Receptors - genetics ; Female ; Humans ; Kaplan-Meier Estimate ; Leukocyte Count ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Lymphocytes ; Male ; Middle Aged ; Multivariate Analysis ; Neutrophils ; Prognosis ; Retrospective Studies ; Risk Factors ; ROC Curve</subject><ispartof>Oncotarget, 2016-05, Vol.7 (18), p.26916-26924</ispartof><rights>Copyright: © 2016 Berardi et al. 2016</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-1ad8abab6426eed4b47fd4924b852ea058a8b06cc906a26c1514137729b2f8423</citedby><cites>FETCH-LOGICAL-c354t-1ad8abab6426eed4b47fd4924b852ea058a8b06cc906a26c1514137729b2f8423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042025/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042025/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27029035$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Berardi, Rossana</creatorcontrib><creatorcontrib>Rinaldi, Silvia</creatorcontrib><creatorcontrib>Santoni, Matteo</creatorcontrib><creatorcontrib>Newsom-Davis, Thomas</creatorcontrib><creatorcontrib>Tiberi, Michela</creatorcontrib><creatorcontrib>Morgese, Francesca</creatorcontrib><creatorcontrib>Caramanti, Miriam</creatorcontrib><creatorcontrib>Savini, Agnese</creatorcontrib><creatorcontrib>Ferrini, Consuelo</creatorcontrib><creatorcontrib>Torniai, Mariangela</creatorcontrib><creatorcontrib>Fiordoliva, Ilaria</creatorcontrib><creatorcontrib>Bower, Marc</creatorcontrib><creatorcontrib>Cascinu, Stefano</creatorcontrib><title>Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy</title><title>Oncotarget</title><addtitle>Oncotarget</addtitle><description>We aimed to assess the prognostic role of neutrophilia, lymphocytopenia and the neutrophil-to-lymphocyte ratio (NLR), and to design models to define the prognosis of patients receiving first-line chemo- or targeted therapy for advanced non-small cell lung cancer (NSCLC).
We retrospectively analysed 401 consecutive patients with advanced NSCLC treated with first line chemo- or targeted therapy. Patients were stratified into two groups with pre-treatment NLR ≥ 3.7 (Group A) vs. < 3.7 (Group B). The best NLR cut-off was identified by ROC curve analysis.
At baseline 264 patients had NLR≥3.7 (Group A), whilst 137 had lower NLR (Group B). Median OS was 10.8 months and 19.4 months in the two groups (p < 0.001), while median PFS was 3.6 months and 5.6 months, respectively (p = 0.012). At multivariate analysis, ECOG-PS≥2, stage IV cancer, non-adenocarcinoma histology, EGFR wild-type status and NLR were predictors of worse OS. Stage IV cancer, wild type EGFR status and NLR≥3.7 were independent prognostic factors for worse PFS. Patients were stratified according to the presence of 0-1 prognostic factors (8%), 2-3 factors (73%) and 4-5 factors (19%) and median OS in these groups was 33.7 months, 14.6 months and 6.6 months, respectively (p < 0.001). Similarly, patients were stratified for PFS based on the presence of 0-1 prognostic factor (15%), 2 factors (41%) and 3 factors (44%). The median PFS was 8.3 months, 4.6 months and 3.3 months respectively (p < 0.001).
Pre-treatment NLR is an independent prognostic factor for patients with advanced NSCLC treated with first-line therapies.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Area Under Curve</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Clinical Research Papers</subject><subject>Disease-Free Survival</subject><subject>ErbB Receptors - genetics</subject><subject>Female</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Leukocyte Count</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Lymphocytes</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neutrophils</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>ROC Curve</subject><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpVkUtv3SAQhVHVqImS7LuKWHbjBDDYeBOpivqSIrWLdo3GeHwvkQ0O4FvlR_Q_l3vzaDoLQJrvHAYOIe85u-S6qcVV8DZkiBvMl7pm3RtywjvZVUKp-u2r8zE5T-mOlVKy1aJ7R45Fy0THanVC_vyIYeNDys7SOQw4JZoDXSIOzmaa1rhzO5io83SB7NDnRH-7vKUw7MBbHKgPvkozTBO1WJZp9Rtq961Ic0TIBTkIRhdTribnkdotzqGioRCH6QuStxhheTgjRyNMCc-f9lPy6_Onnzdfq9vvX77dfLytbK1krjgMGnroGykaxEH2sh0H2QnZayUQmNKge9ZY27EGRGO54pLXbSu6XoxaivqUXD_6Lms_42DLuyJMZoluhvhgAjjzf8e7rdmEnVFMCiZUMfjwZBDD_Yopm9ml_QeAx7AmwzUXel-yoOwRtTGkFHF8uYYzcwjS_AvS7IMskovX470InmOr_wLP26Bl</recordid><startdate>20160503</startdate><enddate>20160503</enddate><creator>Berardi, Rossana</creator><creator>Rinaldi, Silvia</creator><creator>Santoni, Matteo</creator><creator>Newsom-Davis, Thomas</creator><creator>Tiberi, Michela</creator><creator>Morgese, Francesca</creator><creator>Caramanti, Miriam</creator><creator>Savini, Agnese</creator><creator>Ferrini, Consuelo</creator><creator>Torniai, Mariangela</creator><creator>Fiordoliva, Ilaria</creator><creator>Bower, Marc</creator><creator>Cascinu, Stefano</creator><general>Impact Journals LLC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160503</creationdate><title>Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy</title><author>Berardi, Rossana ; Rinaldi, Silvia ; Santoni, Matteo ; Newsom-Davis, Thomas ; Tiberi, Michela ; Morgese, Francesca ; Caramanti, Miriam ; Savini, Agnese ; Ferrini, Consuelo ; Torniai, Mariangela ; Fiordoliva, Ilaria ; Bower, Marc ; Cascinu, Stefano</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-1ad8abab6426eed4b47fd4924b852ea058a8b06cc906a26c1514137729b2f8423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Area Under Curve</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Clinical Research Papers</topic><topic>Disease-Free Survival</topic><topic>ErbB Receptors - genetics</topic><topic>Female</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Leukocyte Count</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Lymphocytes</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neutrophils</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>ROC Curve</topic><toplevel>online_resources</toplevel><creatorcontrib>Berardi, Rossana</creatorcontrib><creatorcontrib>Rinaldi, Silvia</creatorcontrib><creatorcontrib>Santoni, Matteo</creatorcontrib><creatorcontrib>Newsom-Davis, Thomas</creatorcontrib><creatorcontrib>Tiberi, Michela</creatorcontrib><creatorcontrib>Morgese, Francesca</creatorcontrib><creatorcontrib>Caramanti, Miriam</creatorcontrib><creatorcontrib>Savini, Agnese</creatorcontrib><creatorcontrib>Ferrini, Consuelo</creatorcontrib><creatorcontrib>Torniai, Mariangela</creatorcontrib><creatorcontrib>Fiordoliva, Ilaria</creatorcontrib><creatorcontrib>Bower, Marc</creatorcontrib><creatorcontrib>Cascinu, Stefano</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Berardi, Rossana</au><au>Rinaldi, Silvia</au><au>Santoni, Matteo</au><au>Newsom-Davis, Thomas</au><au>Tiberi, Michela</au><au>Morgese, Francesca</au><au>Caramanti, Miriam</au><au>Savini, Agnese</au><au>Ferrini, Consuelo</au><au>Torniai, Mariangela</au><au>Fiordoliva, Ilaria</au><au>Bower, Marc</au><au>Cascinu, Stefano</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy</atitle><jtitle>Oncotarget</jtitle><addtitle>Oncotarget</addtitle><date>2016-05-03</date><risdate>2016</risdate><volume>7</volume><issue>18</issue><spage>26916</spage><epage>26924</epage><pages>26916-26924</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><abstract>We aimed to assess the prognostic role of neutrophilia, lymphocytopenia and the neutrophil-to-lymphocyte ratio (NLR), and to design models to define the prognosis of patients receiving first-line chemo- or targeted therapy for advanced non-small cell lung cancer (NSCLC).
We retrospectively analysed 401 consecutive patients with advanced NSCLC treated with first line chemo- or targeted therapy. Patients were stratified into two groups with pre-treatment NLR ≥ 3.7 (Group A) vs. < 3.7 (Group B). The best NLR cut-off was identified by ROC curve analysis.
At baseline 264 patients had NLR≥3.7 (Group A), whilst 137 had lower NLR (Group B). Median OS was 10.8 months and 19.4 months in the two groups (p < 0.001), while median PFS was 3.6 months and 5.6 months, respectively (p = 0.012). At multivariate analysis, ECOG-PS≥2, stage IV cancer, non-adenocarcinoma histology, EGFR wild-type status and NLR were predictors of worse OS. Stage IV cancer, wild type EGFR status and NLR≥3.7 were independent prognostic factors for worse PFS. Patients were stratified according to the presence of 0-1 prognostic factors (8%), 2-3 factors (73%) and 4-5 factors (19%) and median OS in these groups was 33.7 months, 14.6 months and 6.6 months, respectively (p < 0.001). Similarly, patients were stratified for PFS based on the presence of 0-1 prognostic factor (15%), 2 factors (41%) and 3 factors (44%). The median PFS was 8.3 months, 4.6 months and 3.3 months respectively (p < 0.001).
Pre-treatment NLR is an independent prognostic factor for patients with advanced NSCLC treated with first-line therapies.</abstract><cop>United States</cop><pub>Impact Journals LLC</pub><pmid>27029035</pmid><doi>10.18632/oncotarget.8309</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1949-2553 |
ispartof | Oncotarget, 2016-05, Vol.7 (18), p.26916-26924 |
issn | 1949-2553 1949-2553 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5042025 |
source | PubMed Central |
subjects | Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Area Under Curve Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Clinical Research Papers Disease-Free Survival ErbB Receptors - genetics Female Humans Kaplan-Meier Estimate Leukocyte Count Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms - pathology Lymphocytes Male Middle Aged Multivariate Analysis Neutrophils Prognosis Retrospective Studies Risk Factors ROC Curve |
title | Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T16%3A22%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20models%20to%20predict%20survival%20in%20patients%20with%20advanced%20non-small%20cell%20lung%20cancer%20treated%20with%20first-line%20chemo-%20or%20targeted%20therapy&rft.jtitle=Oncotarget&rft.au=Berardi,%20Rossana&rft.date=2016-05-03&rft.volume=7&rft.issue=18&rft.spage=26916&rft.epage=26924&rft.pages=26916-26924&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.8309&rft_dat=%3Cproquest_pubme%3E1812888884%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c354t-1ad8abab6426eed4b47fd4924b852ea058a8b06cc906a26c1514137729b2f8423%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1812888884&rft_id=info:pmid/27029035&rfr_iscdi=true |